BioCentury
ARTICLE | Management Tracks

Shao out as Sorrento CFO; plus changes at Kronos, Rome and Alveo

August 20, 2020 12:46 AM UTC

Sorrento Therapeutics Inc. (NASDAQ:SRNE) terminated Jiong Shao as EVP and CFO. He is succeeded as CFO by Najjam Asghar, who is the company’s chief accounting officer. Sorrento did not give a reason for its decision. The company is developing therapies to treat cancer and pain, as well as a COVID-19 diagnostics and treatments.

Cancer company  Kronos Bio Inc. hired Yasir Al-Wakeel as CFO and head of corporate development, a new position. He was chief financial and strategy officer of Neon Therapeutics Inc. Last month, Kronos purchased an entire patent portfolio of discontinued spleen tyrosine kinase (SYK) inhibitors from Gilead Sciences Inc. (NASDAQ:GILD) (see “Bischofberger Revisits Gilead Castoff”)...